Neuland Laboratories Limited (NEULANDLAB) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Neuland Laboratories enters its Q1 FY27 results following a record-breaking fiscal year that saw the company scale its Custom Manufacturing Solutions (CMS) pipeline to 98 active projects. Investors will be focused on whether the company can maintain its operating momentum as it transitions from a record Q4 FY26 performance toward its long-term growth targets.

Neuland Laboratories Limited Q1 Results Date and Time

The company has scheduled a board meeting for August 5, 2026, to approve the unaudited Q1 FY27 financial results.

The earnings conference call is scheduled for August 5, 2026, at 17:30 Hrs IST.

What to expect from Neuland Laboratories Limited's Q1 FY27 results

Neuland Laboratories' Q1 FY27 performance is expected to show YoY growth against the Q1 FY26 base of Rs. 300.6 Cr, supported by a favorable USD/INR tailwind and a growing CMS order book. While Q4 FY26 revenue reached a record Rs. 788.7 Cr, management has characterized that quarter as inherently uneven, suggesting a potential moderation in sequential development revenue. EBITDA margins are expected to normalize toward the company's guided sustainable band of 25-30% after the exceptional 40.5% margin recorded in Q4 FY26. Ongoing geopolitical tensions in the Red Sea continue to pose a freight cost headwind, while the company remains focused on its capital-intensive expansion, including the Unit 1 capacity addition of 120.5 KL and the commissioning of the Peptide Module-1 facility in FY27.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress against long-term aspirational targets and recent project milestones.

• Revenue CAGR — 18-20% aspirational target — Reaffirmed in Q4 FY26
• EBITDA margin — 25-30% sustainable range — FY26 actual at 29.4%
• Peptide Module-1 — Ready and operational in FY27 — On track as of Q4 FY26

Strategic Capex and Capacity Expansion: Tracking the execution of major infrastructure investments to support future growth.

• Unit 1 expansion — Investment of Rs. 143.4 Cr for 120.5 KL capacity — 12-18 month timeline from May 2026
• Peptide production suite — Investment of Rs. 1,000 Cr plus — Open-ended timeline
• Genome Valley R&D Centre — 140k Sq Feet leased facility — Board approved

Operating Metric Trajectory: Assessing the sustainability of CMS project conversion and revenue quality.

• Active CMS projects — 98 total as of Q4 FY26 — Growth from 97 in Q4 FY25
• CMS Development revenue — Rs. 488 Cr in Q4 FY26 — Assessment of run-rate sustainability
• Working capital — 137 days of sales in Q4 FY26 — Improvement from 145 days in Q3 FY26

Risks and Headwinds to Monitor: Evaluating external factors impacting margin and supply chain stability.

• Freight costs — Elevated due to Red Sea conflict — Ongoing monitoring for margin impact
• Revenue lumpiness — Inherently uneven shipments — Management guidance remains conservative
• Raw material volatility — Budgeted conservatively — Potential impact on quarterly realizations